bioAffinity Technologies to present data on sputum-based asthma, COPD inflammation test at CHEST 2026
BIAF•bioAffinity Technologies will present research on investigational sputum-based tests for asthma and COPD inflammation at CHEST 2026 on Oct. 20, 2026, in Phoenix. A related clinician-focused discussion is scheduled for Oct. 21.
1. Research presentation
The company said study findings indicate its sputum-based approach can detect multiple inflammation-related biomarkers, with the aim of profiling patients for precision monitoring over time. The work uses bioAffinity Technologies’ flow cytometry and AI platform, extending technology used in its CyPath Lung diagnostic into inflammatory lung disease.
